JMDC, Gene Techno Science, Astellas Venture Management and Nissay Capital contributed to a $25.8m round for the heart failure treatment developer.
Heartseed, a Japan-based developer of treatments for heart failure (HF), has secured ¥2.8bn ($25.8m) in series B funding from investors including corporates JMDC, Gene Techno Science, Astellas and Nippon Life.
Medical data technology provider JMDC and biopharmaceutical company Gene Techno Science invested directly while pharmaceutical firm Astellas, insurer Nippon Life and financial services firms SBI and Sumitomo Mitsui Banking Corporation took part through Astellas Venture Management, Nissay Capital, SBI Investment and SMBC Capital.
Founded in 2015, Heartseed is developing cardiomyocytes…
